Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway. [1] They appear potentially useful for the diagnosis of systemic lupus erythematosus as of 2015. [2]
Medical use
CB-CAPs can be used in the diagnosis and monitoring of SLE. [3] Their efficacy is aided by the ability to be measured throughout the lifespans of erythrocytes, b-lymphocytes. [4]
Research
Research into the development of CB-CAPs has been advocated by the Lupus Foundation of America. [5]
References
- ^ Ramsey-Goldman, Rosalind; Li, Jian; Dervieux, Thierry; Alexander, Roberta Vezza (21 August 2017). "Cell-bound complement activation products in SLE". Lupus Science & Medicine. 4 (1): e000236. doi: 10.1136/lupus-2017-000236. PMC 5704741. PMID 29214038.
- ^ Abulaban, Khalid M.; Brunner, Hermine I. (5 December 2014). "Biomarkers for Childhood-Onset Systemic Lupus Erythematosus". Current Rheumatology Reports. 17 (1): 471. doi: 10.1007/s11926-014-0471-2. PMC 4980820. PMID 25475594.
- ^ Ahearn, Joseph M.; Liu, Chau-Ching; Manzi, Susan (6 November 2017). "Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification". Expert Review of Clinical Immunology. 13 (12): 1133–1142. doi: 10.1080/1744666X.2017.1392238. PMID 29025354. S2CID 205914139.
- ^ Wallace, Daniel; Hahn, Bevra Hannahs (27 September 2012). Dubois' Lupus Erythematosus and Related Syndromes E-Book: Expert Consult - Online and Print. Elsevier Health Sciences. ISBN 978-1455728176 – via Google Books.
- ^ "Exagen and the Lupus Foundation of America Partner on New Initiative to Reduce the Time to an Accurate Lupus Diagnosis". Lupus Foundation of America.
Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway. [1] They appear potentially useful for the diagnosis of systemic lupus erythematosus as of 2015. [2]
Medical use
CB-CAPs can be used in the diagnosis and monitoring of SLE. [3] Their efficacy is aided by the ability to be measured throughout the lifespans of erythrocytes, b-lymphocytes. [4]
Research
Research into the development of CB-CAPs has been advocated by the Lupus Foundation of America. [5]
References
- ^ Ramsey-Goldman, Rosalind; Li, Jian; Dervieux, Thierry; Alexander, Roberta Vezza (21 August 2017). "Cell-bound complement activation products in SLE". Lupus Science & Medicine. 4 (1): e000236. doi: 10.1136/lupus-2017-000236. PMC 5704741. PMID 29214038.
- ^ Abulaban, Khalid M.; Brunner, Hermine I. (5 December 2014). "Biomarkers for Childhood-Onset Systemic Lupus Erythematosus". Current Rheumatology Reports. 17 (1): 471. doi: 10.1007/s11926-014-0471-2. PMC 4980820. PMID 25475594.
- ^ Ahearn, Joseph M.; Liu, Chau-Ching; Manzi, Susan (6 November 2017). "Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification". Expert Review of Clinical Immunology. 13 (12): 1133–1142. doi: 10.1080/1744666X.2017.1392238. PMID 29025354. S2CID 205914139.
- ^ Wallace, Daniel; Hahn, Bevra Hannahs (27 September 2012). Dubois' Lupus Erythematosus and Related Syndromes E-Book: Expert Consult - Online and Print. Elsevier Health Sciences. ISBN 978-1455728176 – via Google Books.
- ^ "Exagen and the Lupus Foundation of America Partner on New Initiative to Reduce the Time to an Accurate Lupus Diagnosis". Lupus Foundation of America.